glp-1 obesity drug market forecast 2030 drugs to reshape pharma landscape GLP-1 Market Industry Trends and

Description

Thats because insurers sometimes consider weight management cosmetic in nature rather than a medical necessity, even though the American Medical Association considers obesity a chronic disease

Rising global prevalence of obesity and type 2 diabetes is a primary growth driver for the market

A: According to ro.co, if insurance denies medication coverage: Ro's concierge can file formal appeals with additional supporting documentation You can explore manufacturer discount/savings programs (if eligible with commercial insurance) You can switch to cash-pay medication options You can try alternative GLP-1 medication that may have better coverage You can cancel membership without penalty (before medication dispensed) Many initial denials are overturned on appeal with proper documentation, though success is not guaranteed